The Diagnostic Yield of the Multidisciplinary Discussion in Patients With COVID-19 Pneumonia

Fiorella Calabrese*, Federica Pezzuto¹, Chiara Giraudo², Luca Vedovelli¹, Francesco Fortarezza¹, Claudia Del Vecchio³, Francesca Lunardi¹, Anna Sara Fraia², Elisabetta Cocconcelli¹, Stefania Edith Vuljan¹, Dario Gregori¹, Andrea Crisanti³, Elisabetta Balestro¹ and Paolo Spagnolo¹

¹ Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Medical School, Padova, Italy, ² Department of Medicine, University of Padova, Medical School, Padova, Italy, ³ Department of Molecular Medicine, University of Padova, Medical School, Padova, Italy

Purpose: The hypothesis of the study was that a multidisciplinary approach involving experienced specialists in diffuse parenchymal lung disease might improve the diagnosis of patients with COVID-19 pneumonia.

Methods: Two pulmonologists, two radiologists, and two pathologists reviewed 27 patients affected by severe COVID-19 pneumonia as the main diagnosis made by non-pulmonologists. To evaluate whether the contribution of specialists, individually and/or in combination, might modify the original diagnosis, a three-step virtual process was planned. The whole lung examination was considered the gold standard for the final diagnosis. The probability of a correct diagnosis was calculated using a model based on generalized estimating equations. The effectiveness of a multidisciplinary diagnosis was obtained by comparing diagnoses made by experienced pulmonologists with those made by non-pulmonologists.

Results: In 19% of cases, the diagnosis of COVID-19-related death was mainly incorrect. The probability of a correct diagnosis increased strikingly from an undedicated clinician to an expert specialist. Every single specialist made significantly more correct diagnoses than any non-pulmonologist. The highest level of accuracy was achieved by the combination of 3 expert specialists ($p = 0.0003$).

Conclusion: The dynamic interaction between expert specialists may significantly improve the diagnostic confidence and management of patients with COVID-19 pneumonia.

Keywords: diagnostic yield, multidisciplinary approach, COVID-19, COVID-19 pneumonia, SARS-CoV-2

INTRODUCTION

Coronavirus disease 19 (COVID-19) was first identified in Wuhan, China, in December 2019 and is now on its second wave. Genetic sequencing of the virus determined that it is a beta coronavirus named severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) (1). Although most patients have a favorable prognosis, pneumonia, and severe hypoxemia secondary to SARS-CoV-2 infection can lead to acute respiratory failure (ARF) and death (2). Elderly male
patients with comorbidities such as obesity, hypertension, diabetes, cardiac disease, and neoplasm also have an increased risk for severe disease and death and need distinct management and higher surveillance levels (3–6). Management remains suboptimal with high mortality rates, particularly among patients admitted to the intensive care unit (ICU).

The integration of all available data from each patient has proven crucial in the management of diffuse parenchymal lung disease (DPLD). Indeed, the international guidelines suggest health professionals with experience in DPLD be involved in patient diagnosis and management in a multidisciplinary approach to achieve the most confident diagnosis and optimize treatment (7). The sudden onset and rapid spread of the COVID-19 pandemic with the high number of infections and deaths have led to a global health emergency. Since this was an unknown disease, the priority has been stemming the infection, which inevitably has limited interaction among experts. As COVID-19 is an extremely complex disease, it would potentially benefit from a multidisciplinary approach even during the pandemic. The hypothesis of this study was therefore that a multidisciplinary approach involving specialists experienced in DPLD (pulmonologists, radiologists, and pathologists) may improve the diagnosis and management of patients with COVID-19 pneumonia, following a decision-making approach similar to what is used in DPLD.

**MATERIALS AND METHODS**

**Study Subjects**

The present study was a critical re-evaluation of deceased patients by an expert team of specialists (pulmonologists, radiologists, and pathologists) routinely involved in multidisciplinary meetings of mainly DPLD (8) but also with robust experience in COVID-19 diagnosis and management (9, 10). We retrospectively studied 27 patients who consecutively died from March to May 2020 in our hospital whose death certificate indicated SARS-CoV-2 infection (detected at least once on nasopharyngeal swab) and severe COVID-19 pneumonia as the main diagnosis made by non-pulmonologists (i.e., emergency room clinicians, general practitioners, specialists in infectious diseases, and anaesthesiologists).

The autopsy was performed according to national and international protocols, as previously described (11). At autopsy, the whole lungs were macroscopically examined. A small sample was taken from the most representative area of lung injury. The sample was in part preserved in RNA later and processed for molecular analyses (see below for molecular processing details) and in part fixed in formalin for routine histology, before and independently from the other additional fragments. Pathological features suggestive of COVID-19 pneumonia (alveolar injury as well as vascular lesions) were quantitatively described using a scoring system, as previously reported (10). Other associated lesions (neoplasia, infectious diseases, aspiration pneumonia, etc.,) were also reported. To confirm the pathological diagnosis of COVID-19 pneumonia, the fragment preserved in RNA later was also processed by real time reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2 [SARS-CoV-2 (2019-nCoV) Centers for Disease Control and Prevention (CDC) Emergency Use Authorized (EUA) Authorized qPCR probe assay primer/probe mix]. An additional fragment was analyzed by culture. Briefly, virus isolation was performed using African green monkey kidney (Vero) cells. When a diffuse, refractile, rounding, cytopathic effect was noted, the Vero cell culture supernatant was passaged to a fresh Vero cell culture tube to ensure reproducibility of the cytopathic effect. SARS-CoV-2 in the supernatant was further confirmed by reverse transcription polymerase chain reaction using primers described previously (12).

In order to define the levels of certainty for a diagnosis of COVID-19 pneumonia, two expert pathologists (FC, FP) scored all cases independently and blinded to clinical and autopsy data. Several parameters, distinguishing distinct anatomic areas (airways, alveolar wall, alveolar space, pleura) and any additional findings were recorded, as previously described (13). Based on morphological/virologic evaluation, four distinct levels of diagnostic certainty were defined: (1) Definite COVID-19 pneumonia: all lung samples showing lesions typical of COVID-19 pneumonia (thrombosis, vascular injury, and/or diffuse alveolar damage/organizing pneumonia), confirmed SARS-CoV-2 lung positivity (both molecular and culture), with no other associated or pre-existing lesions (e.g., foci of bacterial pneumonia, neoplasia), (2) Probable COVID-19 pneumonia: lung samples displaying mainly features of COVID-19 pneumonia (+/- lung SARS-CoV-2 infection) with other associated lesions (e.g., foci of bacterial infection), (3) Possible COVID-19 pneumonia: lung samples showing only focal changes of COVID-19 pneumonia (+/- lung SARS-CoV-2 infection), etc., with more extensive features consistent with alternative diagnoses (i.e., lung cancer/metastasis, etc.,), (4) Non-COVID-19 pneumonia: lung samples not showing any typical lesions, no evidence of SARS-CoV2 infection, and presence of features consistent with alternative diagnoses.

During the autopsy, additional fragments were sampled from both lungs (at least 20 samples for each case) and systematically analyzed, as previously described (13, 14).

Clinical evaluation was performed by two experienced pulmonologists (PS, EB) based on the following data: past and recent medical history including comorbidities, respiratory and systemic signs, and symptoms (type and duration) before hospital admission, imaging, laboratory findings, gas exchange values (FiO2, pO2, and pO2/FiO2) and their changes during hospitalization, and oxygen supplementation. Based on this data, patients were classified as follows: (1) Definite COVID-19 pneumonia: clinical findings typical of COVID-19 such as severe acute respiratory illness (i.e., fever, cough, shortness of breath, hypoxemia) in the absence of an alternative diagnosis that could explain the clinical presentation (15, 16), (2) Probable COVID-19 pneumonia: features of COVID-19 pneumonia associated with findings suggestive of alternative diagnoses (e.g., pleural effusion, clinical and laboratory findings in keeping with heart failure, or signs of bacterial pneumonia), (3) Possible COVID-19 pneumonia: features of COVID-19 pneumonia associated
with prevalent findings consistent with alternative etiologies (e.g., lung cancer, pulmonary metastases, pulmonary edema, heart failure), (4) Non-COVID-19 pneumonia: absence of typical signs/symptoms and laboratory findings of COVID-19 pneumonia in the presence of features consistent with alternative diagnoses (e.g., neoplasm, interstitial lung disease, ischemic heart disease, pulmonary edema).

With regard to the radiological assessment, all chest X-rays and, when available, chest computed tomography (CT) images were assessed by two expert thoracic radiologists (CG,
AF). According to the radiological findings, patients were classified as follows: (1) Definite COVID-19 pneumonia: typical findings of COVID-19 pneumonia, such as bilateral ground-glass opacities and/or consolidations (17), without any signs of alternative diagnoses. (2) Probable COVID-19 pneumonia: features of COVID-19 pneumonia associated with abnormalities such as pleural effusion, cardiomegaly, or Kerley B lines suggestive of cardiac failure, or lobar consolidation suggestive of bacterial pneumonia. (3) Possible COVID-19 pneumonia: features of COVID-19 pneumonia associated with predominant findings of alternative diagnoses (e.g., unilateral pulmonary lesions due to lung cancer, pulmonary bilateral metastatic nodules), (4) Non-COVID-19 pneumonia: no typical signs of COVID-19 with features suggestive of alternative diagnoses (e.g., unilateral pulmonary lesions due to lung cancer, reticular changes secondary to interstitial lung disease).

Data regarding demographics, smoking history, symptoms, comorbidities, treatment, disease duration, serology, radiological, and pathological findings were included in a dedicated database in REDCap. Informed consent was granted by a relative/legal representative of each deceased patient. The study was approved by the local clinical institutional review Board.

**Study Designs**

To evaluate whether the contribution of pulmonologists, radiologists, and pathologists individually and/or in combination, could change the diagnosis originally made by non-pulmonologists, we planned a three-step process, modifying the methodology previously used in the evaluation of patients with DPLD (18).

Briefly, in the first step, two pulmonologists (PS, EB) and two radiologists (CG, AF) independently reviewed clinical and radiological data for each patient, without pathological data, and recorded their individual diagnoses and confidence levels. In the second step, pulmonologists and radiologists discussed their diagnosis and again recorded their individual or shared (in case of disagreement) confidence level. During the third step, pathologists entered the arena and reported the pathological diagnosis performed on a single lung fragment. The final diagnosis derived from the whole lung examination and full organ autopsy and was considered the diagnostic gold standard. Virtual meetings via the Zoom platform were set to allow pulmonologists, radiologists, and pathologists to discuss their interpretation with mutual collaboration (Figure 1).

**Analysis**

All patients were evaluated by pulmonologists and pathologists. One case was not evaluated by radiologists due to lack of radiological data. Specialist scores (for single specialist and for combinations of different specialists) were compared with the full autopsy diagnosis, that was considered to be the true diagnosis, and were recorded as “correct” or “wrong”. Probability of a correct diagnosis (95% confidence interval) was calculated with the method of Wilson using the binconf function of the R package [Hmisc] (19). To explore the effectiveness of a multidisciplinary diagnosis we compared specialist diagnoses with the non-pulmonologist using a model based on generalized estimating equations (GEE) (20) which expand the application of generalized linear models, providing a framework for analyzing correlated data, especially from repeated measures studies where multiple observations are collected from a specific sampling unit (21). In particular, we used a first-order autoregressive correlation structure and a robust standard error estimation to fit our small sample size. The R package [geepack] was used for the analysis (20). We exponentiated GEE results to obtain an odds ratio (95% CI) for each specialist (or combination of specialists) on their ability to formulate a correct diagnosis. All analyses and plotting were conducted on R software v.4.0.2 (22). The full code used for the analysis is available upon request.

**RESULTS**

**Study Population**

For all patients, demographic, clinical, and laboratory data are summarized in Table 1.

The patient population included 15 males (56%) and 12 females (44%) with a median age of 82 years (overall range 42–97 years, interquartile range, 75.5–87.5 years). At disease onset, the main common complaints were dyspnea (89%), fever (74%), and cough (67%). On admission, white blood cells (WBC), and lymphocytes showed a median value of 4.97 × 10^9/L (overall range 0.99–20.36 × 10^9/L, interquartile range 4.14–12.90 × 10^9/L) and 0.79 × 10^9/L (overall range 0.4–1.69 × 10^9/L, interquartile range 0.6425–1.0375 × 10^9/L), respectively. D-dimer levels were available for 19 patients, with a median value of 497 µg/L (overall range 150–3250 µg/L, interquartile range 281–1216 µg/L). Overall, the radiologists assessed 97 chest X-rays and four CTs. On average, for each patient four chest X-rays were available.

**Multistep Process and Interobserver Agreement**

During the first step (Individual diagnosis by Radiologists and Pulmonologists), pulmonologists categorized 11 cases as definite (41%), nine cases as probable (33%), three cases as possible (11%), and four as non-COVID-19 pneumonia (15%). Radiologists classified 11 patients as definite (42%), 11 patients as probable (42%), two patients as possible (8%) and two patients as non-COVID-19 pneumonia (8%). The radiological data of one patient was not available. The overall diagnoses with their corresponding level of confidence are reported in Table 2.

During the second step (Discussion between Radiologists and Pulmonologists), a confident diagnosis was reached in 23 out of 26 cases (88%) with definite COVID-19 pneumonia in eight cases (30%). Following discussion, the diagnosis was changed in six cases, three changes for each specialist group (changes indicated with arrows in Table 2).

In the third step (Group discussion involving Radiologists, Pulmonologists, and Pathologists), the pathologists reported a diagnosis of definite COVID-19 pneumonia in 12 cases (45%), probable COVID-19 pneumonia in nine cases (33%), and possible COVID-19 pneumonia in three cases (11%). Three cases were classified as non-COVID-19 pneumonia (11%) (Table 3).
| ID | Epidemiological data | SARS-COV-2-RT-PCR | Symptoms | Laboratory tests | Symptoms before admission | Ward |
|----|----------------------|-------------------|----------|-----------------|--------------------------|-------|
|    |                      |                  | Fever C | Cough | Dyspnea | WBC 10^9/L | LY 10^9/L | LY % | D-D µL/L | Days |       |
|    | Sex | Age yrs | Smoke | Number of comorbidities | NF SWAB |                  |          |      |          |      |       |
| 1  | M   | 82      | No    | 2       | Positive | 39.5 | Yes | Yes | 15.17 | 0.79 | 5.2 | 311 | 5 | ICU  |
| 2  | F   | 69      | Na    | 2       | Positive | 37.9 | No | Yes | 8.94  | 1.09 | 12.2 | 2063 | 5 | ICU  |
| 3  | M   | 76      | Na    | 3       | Positive | 38   | No | Yes | 9.14  | 1.02 | 7.9  | 736  | 3 | ICU  |
| 4  | M   | 71      | No    | 1       | Positive | 38   | Yes | No  | 17.98 | 1.69 | 9.4  | 684  | 14 | ICU  |
| 5  | F   | 87      | Former| 4       | Positive | 39   | No | Yes | 13.15 | 0.65 | 4.9  | 2929 | 3 | Non-IDU |
| 6  | M   | 79      | Yes   | 3       | Positive | 37.6 | Yes | Yes | 2.68  | 0.62 | 23.1 | 450  | 2 | ICU  |
| 7  | M   | 85      | Former| 5       | Positive | 38   | Yes | Yes | 18.09 | 0.79 | 4.4  | 772  | 4 | Non-IDU |
| 8  | M   | 76      | No    | 2       | Positive | 38   | No | Yes | 5.26  | 1.36 | 25.8 | 150  | 0 | ICU  |
| 9  | F   | 86      | No    | 5       | Positive | <37  | No | Yes | 12.16 | 0.83 | 6.8  | na   | 5 | Non-IDU |
| 10 | M   | 96      | No    | 5       | Positive | <37  | No | Yes | 4.99  | 1.63 | 32   | 150  | 2 | Non-IDU |
| 11 | M   | 86      | No    | 4       | Positive | 38.6 | Yes | Yes | 2.7   | 0.4  | 14.3 | 3250 | 3 | Non-IDU |
| 12 | M   | 77      | No    | 3       | Positive | 39   | Yes | Yes | 4.08  | 0.81 | 19.9 | 497  | 18 | ICU  |
| 13 | F   | 90      | No    | 4       | Positive | 39   | Yes | Yes | 17.83 | 0.77 | 4.3  | Na   | 7 | Non-IDU |
| 14 | M   | 80      | No    | 4       | Positive | 38.5 | Yes | Yes | 0.99  | Na   | Na   | Na   | 2 | Non-IDU |
| 15 | F   | 73      | Na    | 1       | Positive | 37.8 | No | Yes | 5.52  | 0.67 | 12.2 | 345  | 2 | ICU  |
| 16 | M   | 61      | Yes   | 3       | Positive | <37  | No | Yes | 3.02  | Na   | Na   | Na   | 5 | ICU  |
| 17 | M   | 82      | Former| 6       | Positive | 38   | Yes | Yes | 3.72  | 0.46 | 12.4 | 1711 | 3 | Non-IDU |
| 18 | M   | 75      | No    | 0       | Positive | 38.5 | Yes | Yes | 5.48  | 0.49 | 9.8  | 370  | 7 | ICU  |
| 19 | M   | 95      | Former| 3       | Positive | <37  | Yes | Yes | 20.36 | 1.24 | 6.1  | 176  | 2 | Non-IDU |
| 20 | F   | 88      | No    | 5       | Positive | 38.5 | Yes | Yes | 6.45  | 0.94 | 14.6 | 251  | 4 | Non-IDU |
| 21 | F   | 74      | Former| 3       | Positive | 38   | Yes | Yes | 5.2   | 0.8  | 15.4 | 150  | 10 | ICU  |
| 22 | F   | 87      | No    | 3       | Positive | 37   | Yes | Yes | 2.6   | 0.49 | 18.6 | 644  | 8 | Non-IDU |
| 23 | F   | 92      | Na    | 2       | Positive | 38.5 | No | No  | 16.37 | 0.95 | 5.8  | 1660 | 2 | Non-IDU |
| 24 | F   | 90      | Na    | 3       | Positive | 37.7 | Yes | Yes | Na    | Na   | Na   | Na   | 1 | Non-IDU |
| 25 | M   | 83      | Former| 1       | Positive | <37  | Yes | Yes | 5.78  | 0.61 | 10.6 | Na   | 6 | Non-IDU |
| 26 | F   | 97      | Na    | 3       | Positive | 37.9 | Yes | No  | 7.37  | 1.49 | 75.4 | Na   | 0 | Non-IDU |
| 27 | F   | 42      | Na    | 1       | Positive | <37  | No | Yes | 4.32  | 0.70 | 16.2 | Na   | 33 | Non-IDU |

Yrs, years; na, not available; WBC, white blood cells; LY, lymphocytes; D-D, d-dimer; ICU, intensive care unit; RT, reverse transcriptase; PCR, polymerase chain reaction; NF, nasopharyngeal. *List of the most common comorbidities detected: Arterial hypertension, cardiovascular diseases (atrial fibrillation, valvular heart disease, cardiac failure, vasculopathy, angiodysplasia, chronic cerebral vasculopathy, pulmonary embolism, aortic aneurysm), kidney diseases (chronic renal failure, kidney transplant), chronic conditions (diabetes, dyslipidemia, dementia, chronic obstructive pulmonary disease, hyperthyroidism, and connective tissue diseases).
| ID | First step | Second step | Third step | MDT confident diagnosis | Final diagnosis (after the evaluation of all lung specimens and full autopsy) |
|---|---|---|---|---|---|
| **Output** | Pulmonologists | Radiologists | Pulmonologists | Radiologists | Agreement | Pulmonologists + Radiologists | Pathologists | Agreement | **Output** | **Output** |
| 1 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 2 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 3 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 4 | Other | Probable | Other | Probable | No | Other/Probable | Other | Yes, partial | Other | Iatrogenic pneumonia |
| 5 | Probable | Probable | Probable | Yes | Probable | Definite | No | Probable | COVID-19 pneumonia & edema |
| 6 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 7 | Other | Probable | Other | Probable | No | Other/Probable | Probable | Yes, partial | Probable | COVID-19 pneumonia & squamous cell carcinoma |
| 8 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 9 | Other | Other | Other | Other | Yes | Other | Other | Yes, partial | Other | COVID-19 pneumonia & bacterial pneumonia |
| 10 | Other | Probable | Other | Probable | No | Other/Probable | Other | Yes, partial | Other | COVID-19 pneumonia & bacterial pneumonia |
| 11 | Probable | Definite | Probable | Definite → Prob | Yes | Probable | Definite | No | Definite | COVID-19 pneumonia |
| 12 | Possible | Possible | Possible | Possible | Yes | Possible | Possible | Yes | Possible | Squamous cell carcinoma & foci of COVID-19 pneumonia |
| 13 | Definite | Probable | Probable | Probable | Probable | Probable | Probable | No | Definite | COVID-19 pneumonia |
| 14 | Probable | Probable | Probable | Probable | Yes | Probable | Probable | Yes | Probable | COVID-19 pneumonia & bacterial pneumonia |
| 15 | Possible | Possible | Possible | Possible | Yes | Possible | Possible | Yes | Possible | Malignant SFT & foci of COVID-19 pneumonia |
| 16 | Probable | Probable | Probable | Probable | Yes | Probable | Probable | Yes | Probable | COVID-19 pneumonia & Aspergillus bronchopneumonia |
| 17 | Probable | Probable | Probable | Probable | Probable | Probable | Probable | Yes | Probable | COVID-19 pneumonia & bacterial pneumonia |
| 18 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 19 | Other | Other | Other | Other | Yes | Other | Other | Yes | Other | Aspiration and bacterial pneumonia |
| 20 | Probable | Probable | Probable | Probable | Yes | Probable | Yes | Probable | COVID-19 pneumonia & necrotizing granulomas |
| 21 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 22 | Probable | Probable | Probable | Probable | Yes | Probable | Yes | Probable | COVID-19 pneumonia & aspiration pneumonia |
| 23 | Probable | Probable | Probable | Probable | Yes | Probable | Yes | Probable | COVID-19 pneumonia & bacterial pneumonia |
| 24 | Definite | Na | Definite | Na | Na | Na | Possible | Na | Possible | Bacterial pneumonia & foci of COVID-19 pneumonia |
| 25 | Possible | Possible | Possible | Probable | Yes | Probable | Definite | No | Definite | COVID-19 pneumonia |
| 26 | Definite | Definite | Definite | Definite | Yes | Definite | Definite | Yes | Definite | COVID-19 pneumonia |
| 27 | Probable | Probable | Probable | Probable | Yes | Probable | Probable | Yes | Probable | COVID-19 pneumonia & breast cancer metastasis |

na, not available; MDT, multidisciplinary team; Prob, probable; SFT, solitary fibrous tumor.
| ID | COVID-19 related lesions* | Other lesions | Molecular tests | Pathological diagnosis |
|----|--------------------------|--------------|-----------------|-----------------------|
|    |                          |              | Tissue real time RT-PCR | Culture             |                       |
| 1  | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + +              |                       | Definite              |
| 2  | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + Na             |                       | Definite              |
| 3  | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + +              |                       | Definite              |
| 4  | No lesions               | Iatrogenic paracetamol injury | –             | Na                    | Other                 |
| 5  | Diffuse alveolar damage/organizing pneumonia |              | + +              |                       | Definite              |
| 6  | Diffuse alveolar damage/organizing pneumonia |              | +                |                       | Definite              |
| 7  | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Bronchial squamous cell carcinoma | + +              |                       | Probable              |
| 8  | Diffuse alveolar damage/organizing pneumonia |              | + Na             |                       | Definite              |
| 9  | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Bacterial pneumonia | –             | Na                    | Probable              |
| 10 | No lesions               | Bacterial pneumonia | +                | Na                    | Other                 |
| 11 | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + Na             |                       | Definite              |
| 12 | Foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Diffuse squamous cell carcinoma | + Na             |                       | Possible              |
| 13 | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + Na             |                       | Definite              |
| 14 | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Bacterial pneumonia | + +              |                       | Probable              |
| 15 | Foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Malignant pleural solitary fibrous tumor | + –              |                       | Possible              |
| 16 | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Aspergillus invasive bronchopneumonia | + +              |                       | Probable              |
| 17 | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Bacterial pneumonia | + –              |                       | Probable              |
| 18 | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + –              |                       | Definite              |
| 19 | No lesions               | Aspiration/bacterial pneumonia | – –              |                       | Other                 |
| 20 | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Necrotizing granulomas | + +              |                       | Probable              |
| 21 | Diffuse alveolar damage/organizing pneumonia |              | + –              |                       | Definite              |
| 22 | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Aspiration pneumonia | + +              |                       | Probable              |
| 23 | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Bacterial pneumonia | + –              |                       | Probable              |
| 24 | Foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Bacterial pneumonia | + –              |                       | Possible              |
| 25 | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + –              |                       | Definite              |
| 26 | Diffuse alveolar damage/organizing pneumonia and vascular injury |              | + +              |                       | Definite              |
| 27 | Multiple foci of diffuse alveolar damage/organizing pneumonia and vascular injury | Breast cancer metastases/bacterial pneumonia | + –              |                       | Probable              |

RT, reverse transcriptase; PCR, polymerase chain reaction; na: not available. *List of the most common histological findings detected. Diffuse alveolar damage/organizing pneumonia: hyaline membrane, edema, and hemorrhage (acute exudative phase); type 2 pneumocyte hyperplasia, organizing pneumonia, and squamous metaplasia (organizing/proliferative phase). Vascular injury: capillary inflammation, neutrophilic capillaritis, microthrombi, and macrothrombi.

A multidisciplinary discussion led to a confident diagnosis in 18 cases (69%), a partial agreement in three cases (12%), and no agreement in five cases (19%) (Table 2). Additional data derived from examination of the entire lungs and other organs allowed us to finally reach a shared confident diagnosis in all cases. In two cases (8%), COVID-19 pneumonia...
was ruled out, while in three cases (11%), COVID-19 pneumonia was only a marginal pathological process compared to other pathological lesions (Table 2). Examples of definite, probable, possible, and non-COVID-19 pneumonia are given in Figure 2.

The comparison between the diagnosis made by each specialist and the diagnosis made by the team following discussion and with the availability of the autopsy data showed that the ability to formulate a correct diagnosis increased strikingly from a non-pulmonologist to expert specialists, becoming progressively more accurate at different steps (Table 4).

The GEE model showed that every single specialist was able to make a significantly more accurate diagnosis than a non-pulmonologist [OR: 6.33 (95% CI: 1.63–24.5); p = 0.0075]. Of note, the highest level of accuracy was achieved by the combination of three expert specialists (p = 0.0003) who made diagnoses that were about 35 times more accurate [OR: 35.2 (95% CI: 5.07–244)] than a single non-pulmonologist (Table 5, Figure 3). Indeed, in only one case (4%, case number 10) the multidisciplinary team diagnosis was wrong when compared to the gold standard (full autopsy diagnosis) (Table 5, Figure 3). In contrast, the diagnosis formulated by a non-pulmonologist was incorrect in over half of the cases (59%), whereas, the diagnosis formulated by a pulmonologist or a thoracic radiologist was not correct in seven (26%) and six cases (23%), respectively. After discussion, radiologists and pulmonologists incorrectly
diagnosed five cases (19%). After a full autopsy and whole lung examination, pathologists misinterpreted two cases (7%).

**DISCUSSION**

In this study, we showed that the diagnostic accuracy of a multidisciplinary approach involving dedicated DPLD physicians is significantly higher than that of non-pulmonologists in a subset of patients infected by SARS-CoV-2 who died at the University Hospital of Padova and who underwent autopsy. We demonstrated that the dynamic interaction among DPLD experts influenced the level of confidence for the final diagnosis, which improved step by step. In two cases (8%), the diagnosis of COVID-19-related death was incorrect (final diagnosis: no COVID-19 pneumonia), while in three cases (11%), COVID-19 pneumonia was only a marginal feature compared to other pathological lesions. Thus, in 19% of patients the diagnosis was mainly incorrect with consequent inappropriate management. This was the case in two patients, one with severe aspiration pneumonia and the other with carcinomatous lymphangitis who would have required different monitoring and management of care. Inappropriate treatment might have impacted on patient survival and outcome.

The global spread of the SARS-CoV-2 infection was quite unexpected, rapidly leading to a worldwide health emergency. As with any pandemic, patient care has been affected by staffing shortages, a chaotic work environment, and high levels of clinician stress. Clinicians had no choice but to provide care in an extraordinary setting. Moreover, the ICUs rapidly became saturated, and their overcrowding led to the recruitment of non-specialist medical staff, potentially exposing critically ill patients to mismanagement. Based on this distressing experience, COVID-19 health care should be planned adequately during the current second global wave. Today, the challenge is to establish a correct diagnosis taking into consideration several pathological conditions that may mimic and/or overlap with COVID-19 pneumonia, with the aim of optimizing patient management and, consequently, reducing mortality. Although our study consisted of a retrospective analysis (i.e., “a backward path by an expert team”), we believe a multidisciplinary approach involving specialists with experience in DPLD diagnosis and management can be highly beneficial to patient care. The multidisciplinary evaluation has become the diagnostic gold standard for DPLD, as it improves diagnostic confidence and interobserver agreement compared to individual components of the multidisciplinary team in isolation (18, 23), as was the case in our study.

An expert team should be involved in patient evaluation at the very time of hospital admission, particularly when patients are fragile and have severe respiratory failure. The chaotic work environment and the stressful conditions of emergency medical staff, which may make a face-to-face multidisciplinary approach non-realistic, might be successfully overcome by using newer digital technologies. Indeed, during the COVID-19 pandemic, multi-specialist meetings have been suspended and converted into virtual meetings, as occurred in our case.

In the multidisciplinary team of DPLD specialists, radiologists play a key role in that HRCT is largely recognized as a very sensitive and highly specific tool (23–25). During the early phase of the pandemic, CT was seldom performed in COVID-19-positive patients for safety reasons (26, 27). Although chest X-ray proved to be an accurate and reliable method to assess patients with COVID-19, even allowing the development of dedicated scores [CARE referral score] (27), CT plays a crucial role in recognizing alternative diagnoses, especially in patients with pre-existing pulmonary diseases (28–30). Moreover, as recently demonstrated by Borakati and colleagues, it has a higher sensitivity for COVID-19 and its use should be especially promoted in the initial assessment of suspected cases (31). The use of a diagnostic modality other than the gold standard may account for the higher agreement between pathologists and pulmonologists than radiologists in cases of partial agreement.

TABLE 4 | Right and wrong diagnoses by each individual specialist and their combination.

| Overall | 95% CI |
|---------|--------|
| Non-specialist | |
| Wrong | 16 (59.3%) |
| Right | 11 (40.7%) |
| Pulmonologist | |
| Wrong | 7 (25.9%) |
| Right | 20 (74.1%) |
| Radiologist | |
| Wrong | 6 (23.1%) |
| Right | 20 (76.9%) |
| Pathologist | |
| Wrong | 2 (7.4%) |
| Right | 25 (92.6%) |
| Pulmonologist + radiologist | |
| Wrong | 5 (19.2%) |
| Right | 21 (80.8%) |
| Pulmonologist + radiologist + pathologist | |
| Wrong | 1 (3.8%) |
| Right | 25 (96.2%) |

CI, confidence interval.

TABLE 5 | GEE model for estimating the relative correctness of specialists in respect to the non-specialist diagnosis.

| Estimate | Standard error | p-value | 95% CI |
|----------|---------------|---------|--------|
| Pulmonologist | 4.14 | 0.540 | 0.0084 | 1.44–12.0 |
| Radiologist | 4.80 | 0.574 | 0.0063 | 1.56–14.8 |
| Pathologist | 20.5 | 0.821 | 0.0002 | 4.09–102 |
| Pulmonologist + radiologist | 6.33 | 0.691 | 0.0075 | 1.63–24.5 |
| Pulmonologist + radiologist + pathologist | 35.2 | 0.989 | 0.0003 | 5.07–244 |

CI, confidence interval.
are expected to have a significant impact on the quality of the delivered care (32, 33).

After discussion, pulmonologists and radiologists achieved a correct diagnosis in 81% of cases and were about six times more accurate than a single non-pulmonologist emphasizing their acceptable diagnostic yield even when histology is not available. These findings are of particular importance since, in some patients with COVID-19 pneumonia, severe respiratory failure could hamper invasive procedures (such as bronchoscopy) and consequently limit the pathologist’s contribution. However, we then demonstrated that radiologists and pulmonologists incorrectly diagnosed five cases (19%) which could have influenced the decision-making process inducing a different treatment approach, monitoring, and setting of care. Indeed, in the scenario of an overcrowded intensive care unit, extra effort should be made to seek additional opinions by MDT to obtain greater confidence in the diagnostic impression and to improve the management and outcome of these patients.

In our study, as expected, pathologists showed the highest level of confidence between the first diagnostic impression on a single lung fragment compared to the final diagnosis on whole lung examination, with an incorrect diagnosis being made in only two cases. The lung fragments used by pathologists to perform the first diagnosis were similar in size to those obtained by video-assisted thoracic surgery (VATS) that is suggested to be the gold standard tool for the histological diagnosis of DPLD/ILD (23). Invasive procedures such as VATS carry a high risk of mortality, particularly in patients with severe respiratory dysfunction and under mechanical ventilation (34). During the SARS-CoV-2 pandemic, invasive diagnostic procedures involving sampling of the lung parenchyma were discouraged. However, given the critically important contribution that pathologists could provide in the diagnosis of COVID-19 pneumonia, minimally invasive procedures, such as transbronchial lung biopsy/cryobiopsy could be reconsidered in the diagnostic work-up of COVID-19 pneumonia in doubtful cases, when radiological and/or clinical findings suggest the existence of an additional or alternative pathological condition. This is in line with recent expert recommendations (35) suggesting that bronchoscopy, if opportune, can be safely performed in patients with COVID-19, prioritizing minimization of the risk of viral transmission.

Information coming from a full autopsy of COVID-19 patients with the evaluation of numerous lung samples was considered the gold standard for final diagnosis in our case series. Data provided by the most recent autopsy studies have been crucial in improving our knowledge of the pathological substrates of COVID-19. Indeed, because of the contribution of autopsy studies, COVID-19 pneumonia is now recognized as a complex disease involving not only the lung parenchyma but also the vascular compartment with features that include vasculitis, angiogenesis, capillaritis, and micro/macrotromb (10, 14, 36).
The present study has several limitations. First, the study is monocentric, and the study population is relatively small. However, despite this, we were able to implement a GEE model that is robust and provides reliable results even with small sample sizes. Moreover, this is one of the largest monocentric European case series wherein the same lung sampling methodology and analysis was consistently applied.

A multidisciplinary approach to diagnosis and management of patients with COVID-19 requires extra effort by the healthcare providers involved but, if it should be validated, it would have the potential to consistently improve the outcome of this often-fatal disease.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Local Ethics Committee of the University of Padova (4853/A0/20). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

FC, EB, and PS: conceptualization, writing—reviewing and editing, and supervision. FP, FF, and CG: writing original draft—preparation, visualization, and investigation. FL, EC, IV, SV, CD, and AF: resources and investigation. DG and AC: resources, investigation, visualization, and supervision. All authors have wrote, read, and approved the final version of the manuscript.

FUNDING

This research was partially supported by a fellowship from the University of Padova/Intesa San Paolo Vita bank (2020A08).

ACKNOWLEDGMENTS

The authors thank Dr. Judith Wilson for English-language revision.

REFERENCES

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019–nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020) 5:336–44. doi: 10.1038/s41556-020-0095-2

2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. (2020) 8:475–81. doi: 10.1016/S2213-2600(20)30079-5

3. Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. (2020) 55:2001028. doi: 10.1183/13993003.01028-2020

4. Grassi G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. (2020) 8:1201–8. doi: 10.1016/S2213-2600(20)30370-2

5. Figliozzi S, Maschi PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. (2020) 50:E13362. doi: 10.1111/eci.13362

6. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubin S. Similarity in case fatality rates (CFR) of COVID-19/SARS-CoV-2 in Italy and China. J Infect Dev Ctries. (2020) 14:125–8. doi: 10.3855/jidc.12600

7. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Epler GR, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/ERS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2019) 198:E4–68. doi: 10.1164/rccm.201807-1255ST

8. Cocconcelli E, Balestro E, Biondini D, Barbiero G, Polverosi R, Calabrese F, et al. High-resolution computed tomography (HRCT) reflects disease progression in patients with idiopathic pulmonary fibrosis (IPF): relationship with lung pathology. J Clin Med. (2019) 8:399. doi: 10.3390/jcm803039

9. Cocconcelli E, Biondini D, Giraudo C, Lucco S, Bernardinello N, Ficheria G, et al. Clinical features and chest imaging as predictors of intensity of care in patients with COVID-19. J Clin Med. (2020) 9:2990. doi: 10.3390/jcm9090290

10. Borozuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19 Pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. (2020) 33:2156–68. doi: 10.1038/s41379-020-00661-1

11. Basso C, Calabrese F, Sbaraglia M, Del Vecchio C, Carretta G, Saieva A, et al. Feasibility of postmortem examination in the era of COVID-19 pandemic: the experience of a Northeast Italy University Hospital. Virchows Arch. (2020) 477:341–7. doi: 10.1007/s00428-020-02861-1

12. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian Municipality of Vo’. Nature. (2020) 584:425–9. doi: 10.1038/s41586-020-2488-1

13. Calabrese F, Pezzuto F, Fortarezza F, Boscolo A, Lunardi F, Giraudo C, et al. Machine learning-based analysis of alveolar and vascular injury in SARS-CoV-2 acute respiratory failure. J Pathol. (2021). doi: 10.1002/path.5653. [Epub ahead of print].

14. Calabrese F, Pezzuto F, Fortarezza F, Hofman P, Kern I, Panizo A, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European pulmonary pathologists. Virchows Arch. (2020) 477:359–72. doi: 10.1007/s00428-020-02886-6

15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. doi: 10.1056/NEJMoa2002302

17. Kanne JP, Little BP, Chung JH, Elicker BM, Ketai LH. Essentials for radiologists on COVID-19: an update-radiology scientific expert panel. Radiology. (2020) 296:E113–4. doi: 10.1148/radiol.2020200527

18. Eshherty KR, King TE Jr, Raghu G, Lynch JP III, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. (2004) 170:904–10. doi: 10.1164/rccm.200402-147OC

19. Harrell FE, with contributions from Dupont C and many others. Hmisc: Harrell Miscellaneous. (2020). Available online at: https://CRAN.R-project.org/package=Hmisc

20. Hojsigaard S, Hakehoul U, Yan J. The R package gee pkg for generalized estimating equations. J Stat Softw Artic. (2015) 15:1–11. doi: 10.18637/jss.v015.i02

21. Hardin JW. Generalized Estimating Equations (GEE). In: Everitt BS, Howell DC, editors. Encyclopedia of Statistics in Behavioral Science (2005). doi: 10.1002/0470013192.bsa250
22. R Development Core Team. *R: A Language and Environment for Statistical Computing.* Vienna: R Foundation for Statistical Computing (2019).

23. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* (2011) 183:788–824. doi: 10.1164/rccm.2009-040GL

24. Desai SR, Prosch H, Galvin JR. Plain film and HRCT diagnosis of interstitial lung disease. In: Hodler J, Kubik-Huch RA, Von Schulthess GK, editors. *Chapter 4: Diseases of the Chest, Breast, Heart, and Vessels 2019-2022: Diagnostic and Interventional Imaging.* Cham: Springer (2019).

25. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a fleischner society white paper. *Lancet Respir Med.* (2018) 6:138–53. doi: 10.1016/S2213-2600(17)30433-2

26. Fichera G, Stramare R, De Conti G, Motta R, Giraudo C. It’s not over until it’s over: the chameleonic behavior of COVID-19 over a six-day period. *Radiol Med.* (2020) 125:514–6. doi: 10.1007/s11547-020-01203-0

27. Giraudo C, Cavaliere A, Fichera G, Weber M, Motta R, Peloso M, et al. Validation of a composed COVID-19 chest radiography score: the CARE project. *EJ Open Res.* (2020) 6:00359-2020. doi: 10.1183/23120541.00359-2020

28. Larici AR, Cicchetti G, Marano R, Merlino B, Elia L, Calandriello L, et al. Multimodality imaging of COVID-19 pneumonia: from diagnosis to follow-up. A comprehensive review. *Eur J Radiol.* (2020) 131:109217. doi: 10.1016/j.ejrad.2020.109217

29. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Raasch K, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. *Chest.* (2020) 158:106–16. doi: 10.1016/j.chest.2020.04.003

30. Akl EA, Blazic I, Yaacoub S, Frija G, Chou R, Appiah JA, et al. Use of chest imaging in the diagnosis and management of COVID-19: a WHO rapid advice guide. *Radiology.* (2020) 30:203173. doi: 10.1148/radiol.2020203173

31. Borakati A, Perera A, Johnson J, Sood T. Diagnostic accuracy of X-ray versus CT in COVID-19: a propensity-matched database study. *BMJ Open.* (2020) 10:e042946. doi: 10.1136/bmjopen-2020-042946

32. Motta-Basha M, Medved J, Linnau KF, Lynch JB, Wener MH, Kicik G, et al. Policies and guidelines for COVID-19 preparedness: experiences from the University of Washington. *Radiology.* (2020) 296:E26–31. doi: 10.1148/radiol.2019201326

33. Cester G, Giraudo C, Causin F, Boemo DG, Anglani M, Capizzi A, et al. Retrospective analysis of a modified organizational model to guarantee CT workflow during the COVID-19 outbreak in the Tertiary Hospital of Padova, Italy. *J Clin Med.* (2020) 9:3042. doi: 10.3390/jcm9093042

34. Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and non-pulmonary surgery: a case series and comprehensive review of the literature. *Lung.* (2012) 190:373–80. doi: 10.1007/s00408-012-9389-5

35. Luo F, Darwiche K, Singh S, Torrego A, Steinfort DP, Gasparini S, et al. Performing bronchoscopy in times of the COVID-19 pandemic: practice statement from an international expert panel. *Respiration.* (2020) 9:417–22. doi: 10.1159/000507898

36. Calabrese F, Fortarezza F, Giraudo C, Pezzuto F, Faccioli E, Rea F, et al. Two sorts of microthrombi in a patient with coronavirus disease 2019 and lung cancer. *J Thorac Oncol.* (2020) 15:1782–5. doi: 10.1016/j.jtho.2020.08.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Calabrese, Pezzuto, Giraudo, Vedovelli, Fortarezza, Del Vecchio, Lunardi, Fraia, Cocconcelli, Vuljan, Gregori, Crisanti, Balestro and Spagnolo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.